



The Role of Navigated Transcranial Magnetic Stimulation Motor Mapping in Adjuvant Radiotherapy Planning in Patients With Supratentorial Brain Metastases

OPEN ACCESS

Maximilian J. Schwendner^{1,2}, Nico Sollmann^{2,3,4}, Christian D. Diehl¹, Markus Oechsner¹, Bernhard Meyer², Sandro M. Krieg^{2,4*†} and Stephanie E. Combs^{1,5*†}

Edited by:

Sunit Das,
St. Michael's Hospital, Canada

Reviewed by:

Alfredo Conti,
Università degli Studi di Messina, Italy
Brad E. Zacharia,
Penn State Milton S. Hershey Medical
Center, United States
Nir Lipsman,
University of Toronto—University
Health Network, Canada

*Correspondence:

Sandro M. Krieg
sandro.krieg@tum.de
Stephanie E. Combs
stephanie.combs@tum.de

†These authors have contributed
equally to this work

Specialty section:

This article was submitted to
Neuro-Oncology and Neurosurgical
Oncology,
a section of the journal
Frontiers in Oncology

Received: 16 July 2018

Accepted: 11 September 2018

Published: 02 October 2018

Citation:

Schwendner MJ, Sollmann N,
Diehl CD, Oechsner M, Meyer B,
Krieg SM and Combs SE (2018) The
Role of Navigated Transcranial
Magnetic Stimulation Motor Mapping
in Adjuvant Radiotherapy Planning in
Patients With Supratentorial Brain
Metastases. *Front. Oncol.* 8:424.
doi: 10.3389/fonc.2018.00424

¹ Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany,

² Department of Neurosurgery, Klinikum rechts der Isar, Technische Universität München, Munich, Germany, ³ Department of Diagnostic and Interventional Neuroradiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany,

⁴ TUM-Neuroimaging Center, Klinikum rechts der Isar, Technische Universität München, Munich, Germany, ⁵ Department of Radiation Sciences, Institute of Innovative Radiotherapy (iRT), Helmholtz Zentrum München, Munich, Germany

Purpose: In radiotherapy (RT) of brain tumors, the primary motor cortex is not regularly considered in target volume delineation, although decline in motor function is possible due to radiation. Non-invasive identification of motor-eloquent brain areas is currently mostly restricted to functional magnetic resonance imaging (fMRI), which has shown to lack precision for this purpose. Navigated transcranial magnetic stimulation (nTMS) is a novel tool to identify motor-eloquent brain areas. This study aims to integrate nTMS motor maps in RT planning and evaluates the influence on dosage modulations in patients harboring brain metastases.

Materials and Methods: Preoperative nTMS motor maps of 30 patients diagnosed with motor-eloquent brain metastases were fused with conventional planning imaging and transferred to the RT planning software. RT plans of eleven patients were optimized by contouring nTMS motor maps as organs at risk (OARs). Dose modulation analyses were performed using dose-volume histogram (DVH) parameters.

Results: By constraining the dose applied to the nTMS motor maps outside the planning target volume (PTV) to 15 Gy, the mean dose (Dmean) to the nTMS motor maps was significantly reduced by 18.1% from 23.0 Gy (16.9–30.4 Gy) to 18.9 Gy (13.5–28.8 Gy, $p < 0.05$). The Dmean of the PTV increased by 0.6 ± 0.3 Gy (1.7%).

Conclusion: Implementing nTMS motor maps in standard RT planning is feasible in patients suffering from intracranial metastases. A significant reduction of the dose applied to the nTMS motor maps can be achieved without impairing treatment doses to the PTV. Thus, nTMS might provide a valuable tool for safer application of RT in patients harboring motor-eloquent brain metastases.

Keywords: brain mapping, brain metastases, eloquent tumor, navigated transcranial magnetic stimulation, radiotherapy

INTRODUCTION

The most frequent brain tumors in adults are brain metastases. In two of three cases, the primary tumors are lung carcinoma, breast carcinoma, or malignant melanoma (1, 2). For the complex treatment of supratentorial metastases, a multimodal approach including therapeutic options like surgery, radiotherapy (RT), and chemotherapy is recommended (3). For patients with single, large brain metastases, surgery followed by external-beam RT is considered an effective treatment strategy (4, 5).

Regarding surgical therapy, especially tumors in close vicinity of eloquent brain areas like the motor cortex are challenging since preserving neurological function is essential and residual tumor after surgery correlates with local tumor progression (6). Therefore, preoperative functional magnetic resonance imaging (fMRI) and intraoperative neurophysiological monitoring and mapping by direct electrical stimulation (DES) are established tools in neurosurgery to delineate eloquent structures (7–10). Furthermore, navigated transcranial magnetic stimulation (nTMS) is a novel method increasingly applied to non-invasively identify eloquent brain areas prior to surgery. In this context, preoperative motor mapping by nTMS for the resection of motor-eloquent brain metastases improved the outcome of such patients and resulted in a lower rate of residual tumor and less surgery-related paresis when compared to patients without preoperative nTMS motor mappings (11).

Concerning RT planning, target volume delineation including the definition of organs at risk (OARs) is an essential element to provide a safe application of the radiation dose in order to prevent side effects. Structures like the brainstem, optical nerves and optic chiasm, eye lenses, and pituitary gland are routinely considered and spared from radiation (12, 13). A functionally critical structure like the motor cortex is commonly not considered in RT and therefore not spared. However, decline in motor function shortly after treatment has been reported, and it can occur mainly due to radiation necrosis and can eventually even require further surgical treatment (14, 15). Progressive deterioration in motor function has also been reported decades after RT in literature (16).

Against this background, nTMS as a non-invasive method to delineate motor-eloquent areas might also be used in RT; however, it has not yet been integrated in RT of brain metastases. Applying nTMS in radiosurgery, for instance, resulted in improved risk-benefit balancing and dose plan modifications for a small number of patients suffering predominantly from brain metastases (17). The aim of this study was to assess the influence of nTMS motor mapping on RT planning of patients suffering

from supratentorial brain metastases from a dosimetric point of view.

MATERIALS AND METHODS

Ethics

The experimental setup was approved by the local ethics committee of our university (registration number: 5883/13) and was conducted in accordance with the Declaration of Helsinki. Prior to nTMS motor mapping, written informed consent was obtained from all enrolled patients.

Patients

Thirty patients were enrolled prospectively. However, only eleven patients were considered eligible for recalculation of the RT plans. Decision criteria for inclusion of patients for recalculations of RT plans were (1) the mean dose (D_{mean}) of the nTMS motor map, (2) the spatial relationship of the nTMS motor map with high isodose levels, and (3) the distance between the edge of the tumor volume and the nTMS motor map (**Supplementary Table 1**).

All patients received preoperative nTMS motor mapping and underwent surgery for tumor removal at our hospital. As part of the clinical routine, they also underwent detailed clinical examinations pre- and postoperatively and at later time points during follow-up visits. RT to the resection cavity was performed within 7 weeks after surgical treatment (median: 21 days after surgery). Only patients with motor-positive spots in nTMS motor mapping and no previous RT to the irradiation field were considered for this study. Exclusion criteria were general contraindications for nTMS mapping (e.g., metal implants such as cardiac pacemakers), age below 18 years, and pregnancy.

Anatomical Imaging

Amongst other sequences, a fluid attenuated inversion recovery (FLAIR) sequence and a three-dimensional (3D) T1-weighted gradient echo sequence without and with application of a contrast agent (T1Gd+; gadopentetate dimeglumine; Magnograf, Marotrag GmbH, Jena, Germany) were acquired preoperatively on a 3T magnetic resonance imaging (MRI) scanner (Achieva; Philips Medical Systems, Best, The Netherlands). Postoperative MRI was carried out within the first 48 h subsequent to surgery using the same sequences as well as diffusion-weighted and T2*-weighted imaging. Further follow-up imaging at later time points was scheduled according to clinical needs.

For the purpose of precise RT planning, eight of eleven patients received additional MRI during the postoperative course to acquire FLAIR and T1-weighted sequences shortly before RT. Furthermore, cranial computed tomography (CT) imaging was added for RT planning purposes (Somatom Emotion 16; Siemens Healthineers, Erlangen, Germany).

Navigated Transcranial Magnetic Stimulation

The 3D contrast-enhanced, T1-weighted gradient echo sequence was uploaded to a Nexstim eXimia NBS system (version 4.3; Nexstim Plc., Helsinki, Finland) for preoperative nTMS motor mapping. An infrared tracking device (Polaris Spectra;

Abbreviations: 3D, Three-dimensional; BMRC, British Medical Research Council; CT, Computed tomography; DES, Direct electrical stimulation; D_{mean} , Mean dose; DVH, Dose-volume histogram; FLAIR, Fluid attenuated inversion recovery; fMRI, Functional magnetic resonance imaging; HFSRT, Hypofractionated stereotactic RT; LE, Lower extremity; MEG, Magnetoencephalography; MEP, Motor-evoked potential; MRI, Magnetic resonance imaging; nTMS, Navigated transcranial magnetic stimulation; OAR, Organ at risk; PTV, Planning target volume; rMT, Resting motor threshold; RT, Radiotherapy; UE, Upper extremity; VMAT, Volumetric modulated arc therapy; WBRT, Whole brain radiotherapy.

Polaris, Waterloo, Ontario, Canada) combined with a head tracker with reflective sphere markers attached to the patient's forehead was used to align the patient's head with the MRI-based 3D head model using anatomical landmarks, enabling neuronavigation during mapping (18–22). Continuous electromyography with pregelled surface electrodes (Neuroline 720; Ambu, Bad Nauheim, Germany) was derived to record motor-evoked potentials (MEPs) of the M. abductor pollicis brevis, M. abductor digiti minimi, M. flexor carpi radialis, and M. biceps brachii for the upper extremity (UE) and of the M. tibialis anterior and M. gastrocnemius for the lower extremity (LE) (18, 20, 21, 23). Mapping of UE muscle representations was performed with an intensity of 110% of the individual resting motor threshold (rMT), whereas for the mapping of LE muscle representations at least 130% rMT was used during stimulation.

For the identification of motor-positive mapping points, all stimulation spots were analyzed subsequent to the mapping sessions (18, 20, 21). Only stimulation points with an MEP amplitude larger or equal to 50 μ V and an MEP onset latency within the common ranges for UE and LE muscles were defined

motor-positive and therefore considered during surgery and recalculations of RT plans.

For further analyses, the nTMS motor maps were fused with the contrast-enhanced, T1-weighted gradient echo sequences, which was achieved on an external server using the application's automatic fusion algorithm (Elements; Brainlab AG, Munich, Germany; **Supplementary Figure 1**). The fused datasets were then used for linear measurements of the maximum tumor diameter and the distance between the edge of the tumor volume and the respective nTMS motor map in axial slices. In case of infiltrations of the nTMS motor maps by the tumor volume or direct contact of the edge of the tumor and the respective nTMS motor map, a distance of 0 mm was registered. Furthermore, these datasets were used for measurements of the tumor volume using the built-in volumetric assessment tools.

Radiotherapy Planning and Dose Statistics

The nTMS motor maps, fused with the contrast-enhanced, T1-weighted gradient echo sequences, were imported into the RT planning software (Eclipse, version 13.0; Varian Medical Systems,




FIGURE 1 | Integration of motor maps in target volume delineation. This figure shows contrast-enhanced, T1-weighted magnetic resonance imaging (MRI) fused with navigated transcranial magnetic stimulation (nTMS) motor-positive points (white squares) in an exemplary patient case. For radiotherapy (RT) planning, nTMS motor maps were contoured as coherent organs at risk (OARs) in terms of target volume delineation. The planning target volume (PTV) is depicted as a red area.

Palo Alto, CA, USA). In the next step, the nTMS motor maps were fused with the respective planning CT scan using automatic registration combined with additional manual registration in case of any inaccuracy according to visual inspection. This fusion was done directly within the RT planning software. The motor map of each patient, consisting of motor-positive points appearing as 3D objects, was contoured as one single OAR (Figure 1). Fusion of postoperative MRI scans with planning CT scans was performed accordingly.

All patients were treated with hypofractionated stereotactic RT (HFSRT) of seven fractions of 5 Gy prescribed to the 95% isodose level of the planning target volume (PTV) (24). The PTV as the therapeutically crucial radiation volume covers the resection cavity plus contrast-enhancing lesions including a 2 mm safety margin for potential microscopic spread. All RT plans were reevaluated considering the spatial relation of motor maps to isodose levels and the PTV and Dmean of the motor maps (>15 Gy).

As outlined before, eleven patients were considered eligible for recalculations of RT plans (Supplementary Table 1). They obtained two concepts of volumetric modulated arc therapy (VMAT). Regarding the conventional RT plans, plans were optimized without taking into account the nTMS motor maps. Considering nTMS motor maps as an OAR, the RT plans were recalculated by reducing the dose applied to the nTMS motor maps as low as reasonably possible by constraining the dose prescription in this area to 15 Gy (Figure 2). To not compromise the dose applied to the PTV, areas of the nTMS motor maps inside the PTV were not spared.

In these eleven patients, dose statistics regarding the Dmean for the PTV, nTMS motor maps, and OARs (optic chiasm, right optical nerve, left optical nerve, eye lenses, and brainstem) were calculated. For better comparison, calculations of the

proportional overlap of nTMS motor maps with the PTV and isodose levels (90, 80, 70, 50, and 20%) were performed, and the volumes of the nTMS motor maps receiving a specific dose were plotted in dose-volume histograms (DVHs).

Statistical Analyses

All statistical analyses and generation of graphs were done using SPSS (version 24.0; IBM SPSS Statistics for Windows, IBM Corp., Armonk, NY, USA) or Prism (version 7.0; GraphPad Software, La Jolla, CA, USA). Descriptive statistics including mean, median, minimum, maximum, and standard deviation were calculated for patient- and tumor-related characteristics as well as doses and volumes investigated in the present study.

Conventional RT plans not taking nTMS motor maps into consideration (“no nTMS”) were compared to RT plans with constraint to the nTMS motor maps (“nTMS cons”). Therefore, *t*-tests for paired samples with a level of significance set at $p < 0.05$ were performed. The Dmean of the nTMS motor maps, PTV, and OARs consisting of the optic chiasm, optical nerves, eye lenses, and brainstem were selected as comparison criteria. In addition, motor map volumes receiving specific doses were compared accordingly.

RESULTS

Patients and Clinical Information

Eleven patients harboring motor-eloquent supratentorial brain metastases were considered for RT plan recalculations (Table 1, Supplementary Table 1). The maximum follow-up was 13.1 ± 10.8 months on average (1.3–36.0 months), with a mean progression-free survival of 11.7 ± 10.1 months. One male patient died before the regular 3-months follow-up examination, all others completed at least follow-up at this time point.




FIGURE 2 | Dose distribution within motor maps. This figure illustrates radiotherapy (RT) planning in one exemplary patient with a brain metastasis affecting the left central region. The navigated transcranial magnetic stimulation (nTMS) motor-positive points (white squares) are shown on respective contrast-enhanced, T1-weighted magnetic resonance imaging (MRI) and were contoured as an organ at risk (OAR) in the RT plan. Dose distributions covering the range of 5–37.5 Gy are visualized in color-wash mode showing high doses in red and low doses in blue colors. Constraining dose to nTMS motor maps resulted in a shift of dose distributions to lower values.

TABLE 1 | Patient characteristics.

Gender (number of patients)	Females	6
	Males	5
Age at primary treatment (mean and range)		55.9 years (21.1–76.7 years)
Primary tumor (number of patients)	Breast cancer	3
	Non-small cell lung cancer	2
	Ewing sarcoma	2
	Adenocarcinoma	2
	Testicular non-seminoma	1
	Malignant melanoma	1
Tumor-affected hemisphere (number of patients)	Right	4
	Left	7
Extent of resection (number of patients)	>90%	10
	>80%	1
Tumor volume (mean and range)		19.3 cm ³ (2.8 – 62.1 cm ³)
Maximum tumor diameter (mean and range)		3.4 cm (1.9 – 5.2 cm)
Distance tumor–nTMS motor maps (mean and range)		0 mm (0 – 2 mm)
Preoperative motor deficits (number of patients)	BMRC 5/5	3
	4/5	5
	≤3/5	3
Postoperative motor deficits (number of patients)	BMRC 5/5	2
	4/5	6
	≤3/5	3
Motor deficits at 3-months follow-up (number of patients)	BMRC 5/5	6
	4/5	3
	≤3/5	1
Motor deficits at follow-up before tumor progression (number of patients)	BMRC 5/5	5
	4/5	5
	≤3/5	1
Motor deficits at maximum follow-up (number of patients)	BMRC 5/5	5
	4/5	4
	≤3/5	2

This table gives an overview of patient and tumor characteristics for the eleven patients with radiotherapy (RT) plan recalculations. Grading of motor deficits was conducted preoperatively, postoperatively, at 3-months follow-up, at follow-up before progression, and at maximum follow-up according to the British Medical Research Council (BMRC) scale and with respect to the initial side of symptoms, if any. One male patient died before the regular 3-months follow-up examination.

Detailed clinical information including details on the motor status at different time points is shown in **Table 1**. When comparing the preoperative to the postoperative motor status according to the British Medical Research Council (BMRC) scale, two patients declined in motor strength, whereas one patient improved. When comparing the preoperative motor status to the status during 3-months follow-up examinations, no patient showed worsening of motor strength, while four patients showed improved motor strength.

Furthermore, four patients suffered from preoperative paresthesia, two patients from impairment of fine motor skills, and two patients from aphasia. During 3-months follow-up examinations, paresthesia was still found in four patients, while only one patient showed deficits regarding fine motor skills and another patient presented with aphasia.

Tumor recurrence occurring at the site of initial surgery and RT was observed in two patients (4.5 and 22.2 months after surgery, respectively), with both patients undergoing surgical re-resection. Histopathological evaluation of surgically removed tissue confirmed tumor recurrence in both patients without evidence of radiation necrosis in examined tissue probes.

Integration of Navigated Transcranial Magnetic Stimulation During Radiotherapy Planning

Integration of nTMS motor maps in RT planning was feasible in all of the included patients. nTMS motor maps were covered by the PTV by 18.7% on average (**Table 2**). Regarding conventional RT plans, the Dmean of nTMS motor maps was 23.0 Gy (16.9–30.4 Gy; **Figure 3**). With a constraint of 15 Gy to the motor area, the Dmean of nTMS motor maps was 18.9 Gy (13.5–28.8 Gy), thus reducing the dose to nTMS motor maps by 4.1 ± 2.1 Gy (18.1%, $p < 0.05$; **Table 3**, **Figure 3**). The Dmean of the PTV slightly increased by 0.62 ± 0.31 Gy from 35.4 ± 0.1 Gy to 36.0 ± 0.3 Gy (1.7%, $p < 0.05$; **Figure 4**).

Proportional volumes of nTMS motor maps receiving doses equal to or more than 10, 15, 20, 25, 30, and 35 Gy are shown in DVHs (**Figure 5**). The average volume of nTMS motor maps receiving at least 10, 15, and 20 Gy could be reduced by 24.7% ($p < 0.05$), 29.8% ($p < 0.05$), and 26.3% ($p = 0.059$) by constraining the dose applied to the nTMS motor maps outside the PTV (**Supplementary Figure 2**). The Dmean of the anatomical OARs was not affected.

Regarding the 19 patients not considered eligible for recalculation of RT plans, the Dmean was only 9.7 Gy (2.1–18.0 Gy), and the minimum distance between the edge of the tumor and the nTMS motor maps was 8 mm (0–24 mm; **Supplementary Table 1**). These values were significantly different from the respective measurements among the patients considered for RT recalculations ($p < 0.05$).

DISCUSSION

Potential Side Effects of Radiotherapy to Eloquent Brain Areas


In the treatment of brain metastases, whole-brain RT (WBRT), gamma knife radiosurgery, stereotactic radiosurgery, and HFSRT are current treatment strategies, with the choice of the exact treatment approach depending on several factors such as the number and size of metastases, spatial lesion extents, the activity of the systemic disease, and the age and performance status of the individual patient (3, 25). For patients suffering from single, large brain metastases like the patients in this study, surgery combined with HFSRT to the resection cavity is a common treatment strategy (24, 26).

However, all above-mentioned RT options can come at cost of specific side effects. Late neurocognitive deficits are a feared complication especially in WBRT; therefore, local control by stereotactic radiosurgery and fractionated stereotactic RT is often preferred (27–29). Such impairment of neurocognitive function is caused by damage to neural progenitor cells located

TABLE 2 | Spatial relation of motor maps to isodose levels.

	TMS motor maps n PTV	nTMS motor maps n 90% isodose level	nTMS motor maps n 80% isodose level	nTMS motor maps n 70% isodose level	nTMS motor maps n 50% isodose level	nTMS motor maps n 20% isodose level
Mean	18.7%	28.6%	36.7%	43.8%	66.0%	96.5%
Minimum	2.4%	8.3%	13.8%	19.3%	35.1%	83.8%
Maximum	61.7%	70.6%	75.4%	78.1%	89.5%	100.0%
Median	16.6%	29.3%	36.7%	44.7%	68.9%	99.2%

This table shows the spatial relation of the navigated transcranial magnetic stimulation (nTMS) motor maps and the planning target volume (PTV). nTMS motor maps were covered by the PTV by 18.7% (2.4–61.7%) on average and covered by the 90, 80, 70, 50, and 20% isodose levels in 28.6, 36.7, 43.8, 66.0, and 96.5%.




in the subgranular zone of the hippocampus; therefore, it should be spared during RT planning (30). Further treatment-related cerebral injuries are radiation necrosis and white matter injuries that can occur months to years after RT (16, 31). Radiation necrosis may cause motor deficits, sensor deficits, or seizures, depending on the extent and location of the lesion. It occurs in up to 17% of patients treated by stereotactic radiosurgery (32, 33). Risk factors are dose volumes, radiation doses, and fraction sizes (34–36). Tumor location near eloquent areas bears an increased risk of complications in radiosurgical treatment (37). For gamma knife radiosurgery near motor-eloquent areas, the risk of neurological deficits was significantly higher for doses above 20 Gy (38).

Identifying eloquent brain areas by means of nTMS and integrating nTMS data into the radiosurgical planning procedure improved the risk-benefit balancing and led to dose plan modifications as well as a change in radiation dosage for the majority of patients in previous studies (17, 39). For lesions


TABLE 3 | Relative and absolute dose applied to motor maps.

nTMS motor maps	Absolute change of Dmean nTMS cons	Relative change of Dmean nTMS cons
Mean	−4.1 Gy	−18.1%
Minimum	−1.4 Gy	−5.2%
Maximum	−9.0 Gy	−33.2%
Median	−4.1 Gy	−20.0%

This table depicts the absolute and relative changes of the mean dose (Dmean) in navigated transcranial magnetic stimulation (nTMS) motor maps. Radiotherapy (RT) plans with constraints to the nTMS motor maps (“nTMS cons”) achieved an average dose reduction of 4.1 Gy (18.1%) compared to conventional RT plans not taking nTMS motor maps into consideration (“no nTMS”).



at high risk due to larger size or vicinity to critical structures including motor-eloquent areas, HFSRT is often preferred over radiosurgery (40, 41). However, even in patients treated with fractionated stereotactic RT, radiation necrosis occurred in



eloquent brain areas like the primary motor cortex (14). This points out the need of sparing eloquent brain areas in RT, including HFSRT. However, anatomical imaging is currently regarded as the clinical standard for delineation of the target volumes and OARs. Thus, functionally eloquent brain areas are not considered routinely, although they are crucial in terms of risk-benefit balancing and RT planning to minimize neurological deficits. Several methods of functional assessment like fMRI, magnetoencephalography (MEG), and nTMS have been used to identify motor-eloquent areas in the past (39, 42, 43). However, there are currently no established standards in HFSRT regarding functional imaging and dose constraints to eloquent brain structures like the primary motor cortex.

Functional Imaging in Radiotherapy Planning

Lately, nTMS has been implemented as an accurate tool to non-invasively generate preoperative motor maps of the cortex for surgery, resulting in a lower rate of residual tumor and less surgery-related deficits in patients suffering from motor-eloquent metastases (11). In this context, favorable clinical outcome has also been suggested for patients with other intracranial lesions when nTMS motor maps are available for preoperative planning and intraoperative resection guidance (44–46). In terms of RT planning of brain metastases, this is the first study to apply preoperative nTMS with the purpose of decreasing the radiation dose applied to the primary motor cortex.

Currently, eloquent brain areas like the primary motor cortex are commonly not defined as OARs and, hence, not integrated in the process of contouring target volumes in

RT planning. Applying diffusion tensor tractography for dose reductions to the corticospinal tract in radiosurgical treatment of cerebral arteriovenous malformations significantly reduced the risk of motor complications (47). Witt et al. integrated eloquent brain areas identified by fMRI into planning of stereotactic radiosurgery by keeping these structures outside the 30% isodose level (42). Furthermore, Aoyama et al. integrated functional brain imaging by MEG and magnetic resonance axonography into stereotactic irradiation treatment planning in regard of the volume receiving more or equal to 10 Gy and more or equal to 15 Gy (43). A majority of treatment plans was modified, achieving a significant reduction of the volume receiving more or equal to 15 Gy (43). Conti et al. applied functional imaging including fMRI, tractography, and nTMS in radiosurgery (39). Integrating nTMS motor maps in radiosurgery treatment planning of 12 patients with malignant brain tumors achieved an average dose reduction of 25% to these structures (39).

Because nTMS has already been successfully applied in radiosurgery, this study focused on adjuvant RT of supratentorial brain metastases. In our setting, the dose applied to the nTMS motor maps outside the PTV was constrained to 15 Gy. The treatment strategy was HFSRT of 35 Gy subscribed in seven fractions applied to the resection cavity, with a safety margin of 2 mm (24). Due to the small size of the safety margin compared to RT of other brain tumors like glioblastoma, there is a steep gradient of radiation dosage toward circumjacent brain areas. Therefore, in most of the cases, high radiation doses are only applied to a small fraction of the nTMS motor areas. Because this results in a low Dmean of the OARs, these cases were not considered eligible for RT plan recalculations.

The PTV and the 80% isodose level were covered by nTMS motor areas by 18.7 and 36.7% on average. This increases the potential of dose reductions. The Dmean significantly decreased by 18.1% on average, and the volumes of nTMS motor maps receiving at least 10 and 15 Gy were significantly reduced by 24.7 and 29.8%, respectively.

Limitations and Perspectives

This study analyzed eleven patients and applied dose constraints only to cortical motor-eloquent brain areas, not taking tractography into account. Integrating the corticospinal tract by means of diffusion tensor tractography and including a larger number of patients should be considered as the next step. Furthermore, preoperative nTMS motor maps were fused with RT plans based on postoperative imaging. Therefore, shifting of motor areas due to cortical plasticity and perioperative brain shift has not been taken into account for dosimetric analyses. For this retrospective approach, postoperative nTMS motor mapping was categorically not available because only preoperative mapping is currently performed in the context of clinical diagnostics as a method to facilitate preoperative neurosurgical planning and intraoperative resection guidance. Thus, future prospective studies incorporating postoperative nTMS motor maps are highly needed to validate the results of the present study.

As tumor progression mostly occurs shortly after treatment and overall median survival is limited, motor deficits induced by RT might be masked. In the treatment of recurrent or progressive

brain metastases, repeated RT by stereotactic RT or radiosurgery are favorable options, together with new treatment strategies like neoadjuvant radiosurgery before surgical resection; however, repeated treatment once again bears the risk of neurologic impairment for patients with tumors near the motor cortex (48, 49). Overall, survival of patients with brain metastases is limited and motor function is essential for the quality of life; thus, sparing of the motor cortex from higher radiation dosage in selected cases seems reasonable, even in consideration of the unclear distinct impact of photon radiation on the cortex (50, 51).

CONCLUSIONS

Integrating nTMS motor maps in the standard process of RT planning is feasible and valuable in patients harboring motor-eloquent supratentorial metastases. nTMS motor maps considered as OARs in the process of target contouring enable a significant dose reduction to the motor area for selected cases, without impairing the therapeutically crucial dose to the PTV covering the tumor itself. Based on these preliminary results, further prospective studies have to be conducted in order to evaluate the potential benefit, especially the impact on the clinical outcome.

REFERENCES

- Nussbaum ES, Djalilian HR, Cho KH, Hall WA. Brain metastases. Histology, multiplicity, surgery, and survival. *Cancer* (1996) 78:1781–8.
- Taillibert S, Le Rhun E. [Epidemiology of brain metastases]. *Cancer Radiother.* (2015) 19:3–9. doi: 10.1016/j.canrad.2014.11.001
- Gallego Perez-Larraya J, Hildebrand J. Brain metastases. *Handb Clin Neurol.* (2014) 121:1143–57. doi: 10.1016/B978-0-7020-4088-7.00077-8
- Keller A, Dore M, Cebula H, Thillays F, Proust F, Darie I, et al. Hypofractionated stereotactic radiation therapy to the resection bed for intracranial metastases. *Int J Radiat Oncol Biol Phys.* (2017) 99:1179–89. doi: 10.1016/j.ijrobp.2017.08.014
- Pessina F, Navarria P, Cozzi L, Ascolese AM, Maggi G, Riva M, et al. Outcome evaluation of oligometastatic patients treated with surgical resection followed by Hypofractionated Stereotactic Radiosurgery (HSRS) on the tumor bed, for single, large brain metastases. *PLoS ONE* (2016) 11:e0157869. doi: 10.1371/journal.pone.0157869
- Kamp MA, Rapp M, Buhner J, Sloty PJ, Reichelt D, Sadat H, et al. Early postoperative magnet resonance tomography after resection of cerebral metastases. *Acta Neurochir.* (2015) 157:1573–80. doi: 10.1007/s00701-015-2479-4
- Wengenroth M, Blatow M, Guenther J, Akbar M, Tronnier VM, Stippich C. Diagnostic benefits of presurgical fMRI in patients with brain tumours in the primary sensorimotor cortex. *Eur Radiol.* (2011) 21:1517–25. doi: 10.1007/s00330-011-2067-9
- Kamada K, Todo T, Masutani Y, Aoki S, Ino K, Takano T, et al. Combined use of tractography-integrated functional neuronavigation and direct fiber stimulation. *J Neurosurg.* (2005) 102:664–72. doi: 10.3171/jns.2005.102.4.0664
- Sanai N, Berger MS. Mapping the horizon: techniques to optimize tumor resection before and during surgery. *Clin Neurosurg.* (2008) 55:14–9.
- Ottenhausen M, Krieg SM, Meyer B, Ringel F. Functional preoperative and intraoperative mapping and monitoring: increasing safety and efficacy in glioma surgery. *Neurosurg Focus* (2015) 38:E3. doi: 10.3171/2014.10.FOCUS14611
- Krieg SM, Picht T, Sollmann N, Bahrend I, Ringel F, Nagarajan SS, et al. Resection of motor eloquent metastases aided by preoperative nTMS-based motor maps-comparison of two observational cohorts. *Front Oncol.* (2016) 6:261. doi: 10.3389/fonc.2016.00261
- Scoccianti S, Detti B, Gadda D, Greto D, Furfaro I, Meacci F, et al. Organs at risk in the brain and their dose-constraints in adults and in children: a

AUTHOR CONTRIBUTIONS

NS, CD, SK, and SC designed the study. MS, NS, CD, MO, BM, SK, and SC coordinated subject inclusion, data handling, and data storage. MS, NS, CD, and MO were responsible for data analysis and performed statistics. MS, NS, CD, SK, and SC were involved in literature research. MS, NS, CD, MO, BM, SK, and SC drafted the manuscript. The study was supervised by BM, SK, and SC. All authors reviewed the manuscript before submission.

FUNDING

The study was completely financed by institutional grants from the Department of Neurosurgery and the Department of Radiation Oncology. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fonc.2018.00424/full#supplementary-material>

- radiation oncologist's guide for delineation in everyday practice. *Radiother Oncol.* (2015) 114:230–8. doi: 10.1016/j.radonc.2015.01.016
- Kirkpatrick JP, Marks LB, Mayo CS, Lawrence YR, Bhandare N, Ryu S. Estimating normal tissue toxicity in radiosurgery of the CNS: application and limitations of QUANTEC. *J Radiosurg SBRT* (2011) 1:95–107.
- Kim YZ, Kim DY, Yoo H, Yang HS, Shin SH, Hong EK, et al. Radiation-induced necrosis deteriorating neurological symptoms and mimicking progression of brain metastasis after stereotactic-guided radiotherapy. *Cancer Res Treat.* (2007) 39:16–21. doi: 10.4143/crt.2007.39.1.16
- Luther N, Kondziolka D, Kano H, Mousavi SH, Flickinger JC, Lunsford LD. Motor function after stereotactic radiosurgery for brain metastases in the region of the motor cortex. *J Neurosurg.* (2013) 119:683–8. doi: 10.3171/2013.6.JNS122081
- Duffey P, Chari G, Cartledge NE, Shaw PJ. Progressive deterioration of intellect and motor function occurring several decades after cranial irradiation. A new facet in the clinical spectrum of radiation encephalopathy. *Arch Neurol.* (1996) 53:814–8.
- Picht T, Schilt S, Frey D, Vajkoczy P, Kufeld M. Integration of navigated brain stimulation data into radiosurgical planning: potential benefits and dangers. *Acta Neurochir.* (2014) 156:1125–33. doi: 10.1007/s00701-014-2079-8
- Krieg SM. *Navigated Transcranial Magnetic Stimulation in Neurosurgery.* Cham: Springer International Publishing AG 2017 (2017).
- Ruohonen J, Karhu J. Navigated transcranial magnetic stimulation. *Neurophysiol Clin.* (2010) 40:7–17. doi: 10.1016/j.neucli.2010.01.006
- Krieg SM, Lioumis P, Makela JP, Wilenius J, Karhu J, Hannula H, et al. Protocol for motor and language mapping by navigated TMS in patients and healthy volunteers; workshop report. *Acta Neurochir.* (2017) 159:1187–95. doi: 10.1007/s00701-017-3187-z
- Krieg SM, Shibani E, Buchmann N, Gempt J, Foerschler A, Meyer B, et al. Utility of presurgical navigated transcranial magnetic brain stimulation for the resection of tumors in eloquent motor areas. *J Neurosurg.* (2012) 116:994–1001. doi: 10.3171/2011.12.JNS111524
- Sollmann N, Goblirsch-Kolb MF, Ille S, Butenschoen VM, Boeckh-Behrens T, Meyer B, et al. Comparison between electric-field-navigated and line-navigated TMS for cortical motor mapping in patients with brain tumors. *Acta Neurochir.* (2016) 158:2277–89. doi: 10.1007/s00701-016-2970-6
- Sollmann N, Tanigawa N, Bulubas L, Sabih J, Zimmer C, Ringel F, et al. Clinical factors underlying the inter-individual variability of the resting motor threshold in navigated transcranial magnetic stimulation motor mapping. *Brain Topogr.* (2016) 30:98–121. doi: 10.1007/s10548-016-0536-9

24. Specht HM, Kessel KA, Oechsner M, Meyer B, Zimmer C, Combs SE. HFSRT of the resection cavity in patients with brain metastases. *Strahlenther Onkol.* (2016) 192:368–76. doi: 10.1007/s00066-016-0955-2
25. Lu-Emerson C, Eichler AF. Brain metastases. *Continuum* (2012) 18:295–311. doi: 10.1212/01.CON.0000413659.12304.a6
26. Croker J, Chua B, Bernard A, Allon M, Foote M. Treatment of brain oligometastases with hypofractionated stereotactic radiotherapy utilising volumetric modulated arc therapy. *Clin Exp Metastasis* (2016) 33:125–32. doi: 10.1007/s10585-015-9762-x
27. Tallet AV, Azria D, Barlesi F, Spano JP, Carpentier AF, Goncalves A, et al. Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. *Radiat Oncol.* (2012) 7:77. doi: 10.1186/1748-717X-7-77
28. Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. *Lancet Oncol.* (2017) 18:1049–60. doi: 10.1016/S1470-2045(17)30441-2
29. Habets EJ, Dirven L, Wiggeraad RG, Verbeek-de Kanter A, Lycklama ANGJ, Zwinkels H, et al. Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: a prospective study. *Neuro Oncol.* (2016) 18:435–44. doi: 10.1093/neuonc/nov186
30. Gondi V, Tome WA, Mehta MP. Why avoid the hippocampus? A comprehensive review. *Radiother Oncol.* (2010) 97:370–6. doi: 10.1016/j.radonc.2010.09.013
31. Valk PE, Dillon WP. Radiation injury of the brain. *AJNR Am J Neuroradiol.* (1991) 12:45–62.
32. Terakedis BE, Jensen RL, Boucher K, Shrieve DC. Tumor control and incidence of radiation necrosis after reirradiation with stereotactic radiosurgery for brain metastases. *J Radiosurg SBRT* (2014) 3:21–8.
33. Minniti G, D'Angelillo RM, Scaringi C, Trodella LE, Clarke E, Matteucci P, et al. Fractionated stereotactic radiosurgery for patients with brain metastases. *J Neurooncol.* (2014) 117:295–301. doi: 10.1007/s11060-014-1388-3
34. Blonigen BJ, Steinmetz RD, Levin L, Lamba MA, Warnick RE, Breneman JC. Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery. *Int J Radiat Oncol Biol Phys.* (2010) 77:996–1001. doi: 10.1016/j.ijrobp.2009.06.006
35. Ruben JD, Dally M, Bailey M, Smith R, McLean CA, Fedele P. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. *Int J Radiat Oncol Biol Phys.* (2006) 65:499–508. doi: 10.1016/j.ijrobp.2005.12.002
36. Minniti G, Clarke E, Lanzetta G, Osti MF, Trasimeni G, Bozzao A, et al. Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. *Radiat Oncol.* (2011) 6:48. doi: 10.1186/1748-717X-6-48
37. Williams BJ, Suki D, Fox BD, Pelloski CE, Maldaun MV, Sawaya RE, et al. Stereotactic radiosurgery for metastatic brain tumors: a comprehensive review of complications. *J Neurosurg.* (2009) 111:439–48. doi: 10.3171/2008.11.JNS08984
38. Park CY, Choi HY, Lee SR, Roh TH, Seo MR, Kim SH. Neurological change after gamma knife radiosurgery for brain metastases involving the motor cortex. *Brain Tumor Res Treat.* (2016) 4:111–5. doi: 10.14791/btrt.2016.4.2.111
39. Conti A, Pontoriero A, Ricciardi GK, Granata F, Vinci S, Angileri FF, et al. Integration of functional neuroimaging in CyberKnife radiosurgery: feasibility and dosimetric results. *Neurosurg Focus* (2013) 34:E5. doi: 10.3171/2013.2.FOCUS12414
40. Kim YJ, Cho KH, Kim JY, Lim YK, Min HS, Lee SH, et al. Single-dose versus fractionated stereotactic radiotherapy for brain metastases. *Int J Radiat Oncol Biol Phys.* (2011) 81:483–9. doi: 10.1016/j.ijrobp.201005.033
41. Ernst-Stecken A, Ganslandt O, Lambrecht U, Sauer R, Grabenbauer G. Phase II trial of hypofractionated stereotactic radiotherapy for brain metastases: results and toxicity. *Radiother Oncol.* (2006) 81:18–24. doi: 10.1016/j.radonc.2006.08.024
42. Witt TC, Kondziolka D, Baumann SB, Noll DC, Small SL, Lunsford LD. Preoperative cortical localization with functional MRI for use in stereotactic radiosurgery. *Stereotact Funct Neurosurg.* (1996) 66:24–9. doi: 10.1159/000099663
43. Aoyama H, Kamada K, Shirato H, Takeuchi F, Kuriki S, Iwasaki Y, et al. Integration of functional brain information into stereotactic irradiation treatment planning using magnetoencephalography and magnetic resonance axonography. *Int J Radiat Oncol Biol Phys.* (2004) 58:1177–83. doi: 10.1016/j.ijrobp.2003.08.034
44. Krieg SM, Sollmann N, Obermueller T, Sabih J, Bulbas L, Negwer C, et al. Changing the clinical course of glioma patients by preoperative motor mapping with navigated transcranial magnetic brain stimulation. *BMC Cancer* (2015) 15:231. doi: 10.1186/s12885-015-1258-1
45. Frey D, Schilt S, Strack V, Zdunczyk A, Rosler J, Nairala B, et al. Navigated transcranial magnetic stimulation improves the treatment outcome in patients with brain tumors in motor eloquent locations. *Neuro Oncol.* (2014) 16:1365–72. doi: 10.1093/neuonc/nou110
46. Krieg SM, Sabih J, Bulbasova L, Obermueller T, Negwer C, Janssen I, et al. Preoperative motor mapping by navigated transcranial magnetic brain stimulation improves outcome for motor eloquent lesions. *Neuro Oncol.* (2014) 16:1274–82. doi: 10.1093/neuonc/nou007
47. Koga T, Shin M, Maruyama K, Kamada K, Ota T, Itoh D, et al. Integration of corticospinal tractography reduces motor complications after radiosurgery. *Int J Radiat Oncol Biol Phys.* (2012) 83:129–33. doi: 10.1016/j.ijrobp.2011.05.036
48. Ammirati M, Cobbs CS, Linskey ME, Paleologos NA, Ryken TC, Burri SH, et al. The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline. *J Neurooncol.* (2010) 96:85–96. doi: 10.1007/s11060-009-0055-6
49. Asher AL, Burri SH, Wiggins WF, Kelly RP, Boltes MO, Mehrlich M, et al. A new treatment paradigm: neoadjuvant radiosurgery before surgical resection of brain metastases with analysis of local tumor recurrence. *Int J Radiat Oncol Biol Phys.* (2014) 88:899–906. doi: 10.1016/j.ijrobp.2013.12.013
50. Soffietti R, Kocher M, Abacioglu UM, Villa S, Fauchon F, Baumert BG, et al. A European organisation for research and treatment of cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. *J Clin Oncol.* (2013) 31:65–72. doi: 10.1200/JCO.2011.41.0639
51. Maringwa J, Quinten C, King M, Ringash J, Osoba D, Coens C, et al. Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. *Ann Oncol.* (2011) 22:2107–12. doi: 10.1093/annonc/mdlq726

Conflict of Interest Statement: NS received honoraria from Nexstim Plc (Helsinki, Finland). SK is consultant for Nexstim Plc (Helsinki, Finland) and received honoraria from Medtronic (Meerbusch, Germany) and Carl Zeiss Meditec (Oberkochen, Germany). SK and BM received research grants and are consultants for Brainlab AG (Munich, Germany). BM received honoraria, consulting fees, and research grants from Medtronic (Meerbusch, Germany), icotec ag (Altstätten, Switzerland), and Relivant Medsystemy Inc., (Sunnyvale, CA, USA), honoraria and research grants from Ulrich Medical (Ulm, Germany), honoraria and consulting fees from Spineart Deutschland GmbH (Frankfurt, Germany) and DePuy Synthes (West Chester, PA, USA), and royalties from Spineart Deutschland GmbH (Frankfurt, Germany).

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Schwendner, Sollmann, Diehl, Oechsner, Meyer, Krieg and Combs. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.